Pediatrix Medical Group, Inc. - 10-Q Summary (Period Ended Sept 30, 2007)
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2007. Pediatrix Medical Group, Inc. (PMG) operates as a management company for affiliated professional contractors providing pediatric medical services, primarily neonatal intensive care, maternal-fetal medicine, and pediatric cardiology. The company recently expanded into anesthesiology through the acquisition of Fairfax Anesthesiology Associates in September 2007. As of November 5, 2007, there were 48,400,274 shares of common stock outstanding.
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2007 | Nine Months Ended Sept 30, 2007 |
|---|---|---|
| Net Patient Service Revenue | $236.9 million | $678.1 million |
| Net Income | $39.6 million | $101.5 million |
| Diluted EPS | $0.79 | $2.02 |
| Operating Margin | 26.7% | 23.6% |
| Cash and Cash Equivalents | $50.5 million (Balance Sheet) | $50.5 million (Balance Sheet) |
| Working Capital | $64.3 million | $64.3 million |
| Debt | $0.9 million (Total Debt) | $0.9 million (Total Debt) |
| Operating Cash Flow (9mo) | $99.1 million |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 9.8% ($21.1 million) for the quarter and 11.7% ($70.9 million) for the nine months compared to 2006. Growth was driven by acquisitions (39.3% of Q3 increase) and same-unit volume increases (6.1% in Q3, 8.2% in 9 months).
- Profitability: Net income rose 12.5% in the quarter and 10.2% for the nine months. However, the nine-month operating margin decreased from 24.3% to 23.6% due to one-time costs related to stock option reviews and tax obligations.
- Acquisitions: The company acquired seven physician practices in the first nine months of 2007, recording approximately $102.0 million in goodwill. Cash used for acquisitions totaled $102.1 million.
- Share Repurchases: The company initiated a $100 million share repurchase program in August 2007. By September 30, 2007, it had repurchased 1.1 million shares for $67.4 million. The program was completed in November 2007 with 1.6 million shares purchased.
- Stock Option Review Costs: Results of operations included significant costs related to a review of historical stock option practices, including professional fees and payments to cover IRS Section 409A tax obligations on behalf of employees.
Guidance, Outlook, Risks, and Contingencies
Outlook and Commentary: Management expects to improve results of acquired practices through better managed care contracting and operational efficiencies. The company anticipates that funds from operations, cash on hand, and its $225 million Line of Credit (with no outstanding principal balance as of Sept 30, 2007) will be sufficient to meet obligations for the next 12 months.
Risks and Contingencies:
- Legal Proceedings (Stock Options): The SEC has commenced a formal investigation into the company's historical stock option granting practices. A shareholder derivative lawsuit was filed in August 2007 alleging breaches of fiduciary duty. The company is cooperating with authorities and cannot predict the outcome.
- Regulatory Compliance: The company is subject to a five-year Corporate Integrity Agreement with the HHS Office of Inspector General following a $25.1 million settlement regarding neonatal services (1996-1999). Failure to comply could result in penalties or exclusion from federal healthcare programs.
- Tax Uncertainty: The adoption of FIN 48 resulted in a $7.7 million cumulative effect adjustment to retained earnings. The company has a total liability for unrecognized tax benefits of $37.4 million as of September 30, 2007.
- Medical Malpractice: The company faces ongoing litigation risks related to medical malpractice claims, though it maintains liability insurance and self-insures deductibles.
Investor Verification Checklist
- Verify the status and potential financial impact of the SEC investigation and shareholder derivative lawsuit regarding stock option practices.
- Confirm compliance status with the Corporate Integrity Agreement and any new findings from government audits.
- Review the integration progress and financial performance of the seven practices acquired in 2007, particularly the new anesthesiology unit.
- Monitor the resolution of the $3.9 million verdict against an acquired corporation (indemnified by sellers) and the status of post-trial motions.
- Assess the impact of the $100 million share repurchase program on future capital allocation and liquidity.